Incyte | INCY - Assets


Incyte reported $7.87B in Assets for its fiscal quarter ending in June of 2026.





Assets Change Date
Acadia Pharmaceuticals USD 1.74B 137.67M Jun/2026
Agenus USD 186.46M 40.34M Mar/2026
Agios Pharmaceuticals USD 1.11B 76.57M Jun/2026
Alnylam Pharmaceuticals USD 5.56B 429.22M Jun/2026
Amgen USD 95.64B 3.14B Jun/2026
BioCryst Pharmaceuticals USD 557.85M 92.8M Jun/2026
Biogen USD 32.09B 2.6B Jun/2026
BioMarin Pharmaceutical USD 8.59B 996.99M Mar/2026
Bristol-Myers Squibb USD 87.63B 1.16B Jun/2026
Eli Lilly USD 142.28B 25.71B Jun/2026
Exelixis USD 2.59B 250.83M Mar/2026
Gilead Sciences USD 49.36B 6.92B Jun/2026
Incyte USD 7.87B 533.53M Jun/2026
Ionis Pharmaceuticals USD 2.99B 455.5M Jun/2026
MacroGenics USD 217.87M 38.97M Mar/2026
Merck USD 128.68B 8.18B Mar/2026
Moderna USD 10.96B 527M Jun/2026
Nektar Therapeutics USD 763.27M 482.86M Mar/2026
Neurocrine Biosciences USD 5.36B 452.9M Jun/2026
Novartis USD 122.03B 3.5B Jun/2026
Novartis USD 118.53B 7.58B Mar/2026
Pfizer USD 201.13B 6.49B Jun/2026
PTC Therapeutics USD 3.25B 381.37M Jun/2026
Puma Biotechnology USD 202.86M 7.95M Sep/2025
Regeneron Pharmaceuticals USD 41.73B 861.8M Jun/2026
Sarepta Therapeutics USD 3.18B 170.77M Mar/2026
Ultragenyx Pharmaceutical USD 1.26B 32M Jun/2026
Vertex Pharmaceuticals USD 27.42B 938.9M Jun/2026